91 related articles for article (PubMed ID: 20730701)
1. M-118, a novel, low-molecular-weight heparin for the potential treatment of cardiovascular disorders.
Shah H; Gurm HS
Curr Opin Investig Drugs; 2010 Sep; 11(9):1059-65. PubMed ID: 20730701
[TBL] [Abstract][Full Text] [Related]
2. M118--a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes.
Kishimoto TK; Qi YW; Long A; Capila I; Sasisekharan R; Guerrero L; Fier I; Roach J; Venkataraman G
Thromb Haemost; 2009 Nov; 102(5):900-6. PubMed ID: 19888526
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin: a critical analysis of clinical trials.
Green D; Hirsh J; Heit J; Prins M; Davidson B; Lensing AW
Pharmacol Rev; 1994 Mar; 46(1):89-109. PubMed ID: 8190751
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic indications of low molecular weight heparins].
Samama MM; Michaut-Paterno F
Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.
Rao SV; Melloni C; Myles-Dimauro S; Broderick S; Kosinski AS; Kleiman NS; Dzavík V; Tanguay JF; Chandna H; Gammon R; Rivera E; Alexander JH; Fier I; Roach J; Becker RC;
Circulation; 2010 Apr; 121(15):1713-21. PubMed ID: 20368520
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacologic and clinical principles for rational anti-thrombotic preventive treatment with low molecular weight heparin].
Pindur G; Köhler M; Heiden M; Leipnitz C; Rupp KH; Wenzel E
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():1149-55. PubMed ID: 1983502
[TBL] [Abstract][Full Text] [Related]
8. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of low-molecular-weight heparin in cardiovascular medicine.
Hirsh J; Bates SM
Prog Cardiovasc Dis; 2000; 42(4):235-46. PubMed ID: 10661777
[TBL] [Abstract][Full Text] [Related]
10. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin in the treatment of deep venous thrombosis.
Hauer KE
West J Med; 1998 Oct; 169(4):240-4. PubMed ID: 9795594
[TBL] [Abstract][Full Text] [Related]
12. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
[TBL] [Abstract][Full Text] [Related]
13. Heparin and low molecular weight heparin in thrombosis and beyond.
Mousa SA
Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
15. The management of thrombosis in pregnancy: role of low-molecular-weight heparin.
Kher A; Bauersachs R; Nielsen JD
Thromb Haemost; 2007 Apr; 97(4):505-13. PubMed ID: 17393011
[TBL] [Abstract][Full Text] [Related]
16. [State of the art: low-molecular-weight heparin and beyond].
Cimminiello C; Casali G; Vitali L
Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
[TBL] [Abstract][Full Text] [Related]
17. New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin.
Martínez-González J; Rodríguez C
Expert Rev Cardiovasc Ther; 2010 May; 8(5):625-34. PubMed ID: 20450295
[TBL] [Abstract][Full Text] [Related]
18. Treatment of cancer-associated thrombosis: distinguishing among antithrombotic agents.
Pruemer J
Semin Oncol; 2006 Apr; 33(2 Suppl 4):S26-39; quiz S41-2. PubMed ID: 16638458
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight heparins in clinical practice.
Hunt D
South Med J; 1998 Jan; 91(1):2-10. PubMed ID: 9438394
[TBL] [Abstract][Full Text] [Related]
20. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
